Premium
CERNA2: A predictor for clinical progression and poor prognosis in cervical carcinoma
Author(s) -
Wang Min,
Ouyang Jianghua,
Li Huali
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28397
Subject(s) - gene knockdown , cervical carcinoma , medicine , cervical cancer , carcinogenesis , metastasis , carcinoma , cancer research , stage (stratigraphy) , oncology , lymph node , microrna , long non coding rna , pathology , cancer , biology , rna , cell culture , gene , paleontology , biochemistry , genetics
Competing long noncoding RNA 2 (lncRNA 2) for microRNA let‐7b (CERNA2) has emerged as an important regulator of tumorigenesis and cancer progression but the clinical value and regulatory function of CERNA2 is yet to be investigated in cervical carcinoma. In our study, we found the CERNA2 expression was obviously increased in cervical carcinoma tissues compared with adjacent normal cervical tissues. In addition, we observed that metastatic lymph nodes exhibited high levels of CERNA2 expression in contrast to primary cervical carcinoma tissues. Furthermore, high CERNA2 expression was associated with advanced clinical stage, lymph node metastasis, distant metastasis poor histological grade, and short overall survival in cervical carcinoma patients. Moreover, high CERNA2 expression acted as an independent unfavorable predictor for overall survival in cervical carcinoma patients. The cell migration and invasion assays in vitro suggested that knockdown of CERNA2 remarkably inhibited cell migration and invasion in cervical carcinoma. In conclusion, CERNA2 functions as an oncogenic lncRNA and may be as a potential therapeutic target in cervical carcinoma.